News

Aeonsemi Launches Praxium PHY Family for Physical AI Ethernet

Santa Clara, Calif. – September 22, 2026 -- Aeonsemi, Inc. has introduced the Praxium PHY family, a line of multi-gigabit Ethernet transceivers delivering data rates up to 10 Gbps in a 6 x 6 mm QFN package for robots, autonomous vehicles and industrial machines.

Praxium cuts power to as low as 350 mW for 10 Gbps sensor links

The chips support IEEE 802.3ch standards for 10GBASE-T1, 5GBASE-T1 and 2.5GBASE-T1 operation, and use Energy-Efficient Ethernet on lower-speed uplinks to reach the 350 mW figure for asymmetric 10 Gbps connections. The family targets cameras, LiDAR, zone controllers and network backbones inside Physical AI systems where component size and power budgets are constrained.

Chris Paul Joins Owl Ventures as Venture Partner

San Francisco – September 22, 2026 -- Owl Ventures, the world's largest venture capital firm focused on education and workforce innovation, has named NBA legend Chris Paul as Venture Partner, adding a high-profile figure to a firm managing more than $2.2 billion in committed capital.

Owl Ventures backs over 100 companies reaching 700 million users worldwide

The firm operates three global offices and has made over 100 investments in companies helping people learn, prepare for work, and build skills throughout their careers. Its portfolio companies collectively reach more than 700 million users globally.

THOR Industries FY2026 Net Sales Hit $9.61B Despite Margin Pressure

Elkhart, Ind. – September 22, 2026 -- THOR Industries reported fiscal 2026 net sales of $9.61 billion and net income attributable to THOR of $177.5 million, exceeding the high end of its guidance despite a prolonged downturn in the North American RV retail market.

Fourth-quarter net sales reached $2.31 billion as North American shipments fell sharply

THOR posted fourth-quarter net sales of $2.31 billion, net income attributable to THOR of $40.8 million and EBITDA of $130.0 million. Adjusted EBITDA came in at $131.7 million, excluding nonrecurring restructuring costs and investment gains. North American Towable RV net sales declined on a 19.7% drop in unit shipments, with fifth wheel shipments down 34.7%, while gross margin in that segment fell 280 basis points. North American Motorized net sales fell 10.4% on a 13.1% unit shipment decline, with gross margin down 600 basis points.

CHiQ Sponsors Germany's First ITF Junior Wheelchair Tennis Open

Cologne – – September 22, 2026 -- Smart home appliance brand CHiQ sponsored Germany's inaugural ITF Juniors Wheelchair Tournament, held September 19–20 at the Marienburger Sport-Club in Cologne. The event followed CHiQ's August backing of the Para Youth Development Day, marking the company's expansion from grassroots activities into elite youth competition sponsorship.

Tournament draws competitors from five European countries

The field included young athletes from Germany, the Netherlands, Austria, Belgium and the United Kingdom. Both seasoned players and newcomers making their international debut competed, using the event as a springboard toward higher-level tournaments.

Compugen to Detail COM701 Ovarian Cancer Trial Data at Oct. 5 KOL Event

Holon, Israel – September 22, 2026 -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) will host a virtual key opinion leader event on October 5, 2026 at 8:00 AM ET, presenting new detail on COM701, its anti-PVRIG antibody candidate for relapsed platinum-sensitive ovarian cancer (PSOC).

Harvard oncologist to preview MAIA-ovarian trial design and timeline

Oladapo Yeku, M.D., Ph.D., FACP, of Harvard Medical School and Massachusetts General Hospital, will join Compugen management to discuss the randomized MAIA-ovarian adaptive platform trial. The study evaluates COM701 as a maintenance therapy in relapsed PSOC patients, with median progression-free survival data from the interim analysis expected by Q1 2027. COM701 has already shown initial anti-tumor activity and a favorable safety and tolerability profile in Phase 1 studies as monotherapy and in combination regimens.

Edgewise Reveals EDG-7500 Data Targeting Novel Cardiac Muscle Protein

Boulder, Colorado – September 22, 2026 -- Edgewise Therapeutics (Nasdaq: EWTX) disclosed preclinical data showing its lead cardiac drug candidate EDG-7500 improves heart relaxation while preserving systolic function, a mechanism the company says addresses a core driver of hypertrophic cardiomyopathy (HCM) that current therapies do not fully target.

Edgewise screened over 7,000 candidates to isolate a first-in-class RLC modulator

The company's Chief Scientific Officer, Alan Russell, said Edgewise screened more than 7,000 pharmacologically diverse compounds targeting the Regulatory Light Chain (RLC) before selecting molecules exhibiting positive lusitropic properties without compromising systolic performance. "EDG-7500's diastolic-biased profile has the potential to address a central pathologic driver of both symptomatic obstructive and nonobstructive HCM," Russell said.

SystImmune Wins FDA IND Clearance Using Non-Animal Test Methods

Redmond – September 22, 2026 -- SystImmune Inc. has secured U.S. Food and Drug Administration clearance for its Investigational New Drug application for SI-B037, a bispecific antibody, marking the first time the company has built a regulatory submission entirely on New Approach Methodologies (NAMs) rather than traditional animal toxicology studies.

SystImmune replaces animal testing with human organ-on-chip models

The IND package for SI-B037 relied on human organ-on-chip systems and primary human tissue models instead of conventional animal studies to assess nonclinical safety. Dr. Jahan Khalili, Senior Vice President of Research at SystImmune, said the human-relevant models provided a more direct read on a molecule engineered to engage multiple human pathways simultaneously.

Sealed Air Launches ZeroPrep Pouches to Cut Condiment Prep Time

Charlotte, N.C. – September 22, 2026 -- Sealed Air Corporation has launched CRYOVAC® brand ZeroPrep hand-dispensing pouches, a pre-filled packaging format designed to eliminate squeeze bottle preparation and cleanup in restaurant back-of-house operations.

Pre-filled pouches replace rigid squeeze bottles in food service kitchens

Each ZeroPrep pouch includes an easy-open seal and a resealable spout that allows one-handed dispensing of condiments and sauces without drips. The pouches are hermetically sealed until first use, reducing contamination risk by removing the step of transferring condiments into secondary containers.

Cognex to Acquire RealSense for $500M, Enters Robotic Perception Market

Natick, Mass. – September 22, 2026 -- Cognex Corporation (NASDAQ: CGNX) has agreed to acquire RealSense, the market leader in depth-sensing cameras for robotic perception and Physical AI, for approximately $500 million in cash, the company announced. The deal, financed entirely from Cognex's existing cash and investments, is expected to close in the fourth quarter of 2026 subject to customary conditions.

RealSense revenue is set to grow more than 50% to $80-90 million in 2026

RealSense, originally founded by Intel in 2014 and spun out as an independent company in 2025, is projected to generate $80 million to $90 million in revenue this year, representing growth of more than 50% over the prior year. The company's 3D perception technology serves fixed-arm robotics, autonomous mobile robots, quadrupeds and humanoids.

Zocdoc Expands Booking Network to AI Platforms, Search Engines

NEW YORK – September 22, 2026 -- Zocdoc announced a platform expansion that makes healthcare providers bookable beyond Zocdoc.com through a single connection to its Care Access Network, which already includes Amazon Health AI, Gemini, Yelp, Healthgrades, Blue Shield of California and multiple search engines.

Patients now search for care across a growing number of fragmented channels

A new national Zocdoc survey found that 69% of patients who search for a new doctor check multiple places, from AI platforms and insurance directories to search engines and review sites. More than 1 in 3 patients have switched doctors because scheduling was too difficult, while 43% would consider switching to a provider that is easier to book.

Subscribe to News